ATE156859T1 - Varianten von pai-2 - Google Patents

Varianten von pai-2

Info

Publication number
ATE156859T1
ATE156859T1 AT91901253T AT91901253T ATE156859T1 AT E156859 T1 ATE156859 T1 AT E156859T1 AT 91901253 T AT91901253 T AT 91901253T AT 91901253 T AT91901253 T AT 91901253T AT E156859 T1 ATE156859 T1 AT E156859T1
Authority
AT
Austria
Prior art keywords
variants
pai
pct
sec
compositions
Prior art date
Application number
AT91901253T
Other languages
English (en)
Inventor
Neil Howard Goss
Michael Andrew Richardson
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Application granted granted Critical
Publication of ATE156859T1 publication Critical patent/ATE156859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91901253T 1989-12-20 1990-12-20 Varianten von pai-2 ATE156859T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ792489 1989-12-20

Publications (1)

Publication Number Publication Date
ATE156859T1 true ATE156859T1 (de) 1997-08-15

Family

ID=3774424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91901253T ATE156859T1 (de) 1989-12-20 1990-12-20 Varianten von pai-2

Country Status (10)

Country Link
US (1) US5444153A (de)
EP (1) EP0458937B1 (de)
JP (1) JP2567536B2 (de)
AT (1) ATE156859T1 (de)
AU (1) AU625018B2 (de)
DE (1) DE69031271T2 (de)
DK (1) DK0458937T3 (de)
ES (1) ES2106772T3 (de)
GR (1) GR3025330T3 (de)
WO (1) WO1991009124A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
DE4214999C2 (de) * 1992-05-06 1994-07-14 Behringwerke Ag Reinigung von Plasminogen-Aktivator-Inhibitor 2 durch Immunaffinitätschromatographie
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6071922A (en) 1997-03-19 2000-06-06 Emory University Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activities of 1,3-oxaselenolane nucleosides
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
US6344189B1 (en) 1998-04-01 2002-02-05 Biotech Australia Pty., Ltd. Use of protease inhibitors for treating skin wounds
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
AUPQ582400A0 (en) * 2000-02-24 2000-03-16 Biotech Australia Pty Limited A method of treatment and agents for use therein
US8062637B2 (en) * 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6562572B1 (en) * 2000-09-27 2003-05-13 Mayo Foundation For Medical Education And Research Methods for amplifying nucleic acid sequences
EP2224949B1 (de) * 2007-11-30 2012-10-17 University of Debrecen Verwendung von Plasminogen-Aktivator-Inhibitoren vom Urokinase-Typ zur Behandlung von kornealen Erkrankungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
JPH0655152B2 (ja) * 1984-08-13 1994-07-27 バイオテクノロジー・オーストラリア・ピーテイーワイ・リミテツド ミナクチビンの製造方法
AU608752B2 (en) * 1986-03-13 1991-04-18 Australian National University, The Minactivin produced by recombinant dna technology
IL81879A (en) * 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
DE3722673A1 (de) * 1987-04-18 1989-01-19 Behringwerke Ag Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna
DK0446315T3 (da) * 1989-09-05 1998-01-05 Biotech Australia Pty Ltd Fremgangsmåde til fremstilling af PAI-2

Also Published As

Publication number Publication date
US5444153A (en) 1995-08-22
GR3025330T3 (en) 1998-02-27
EP0458937A4 (en) 1992-04-01
DE69031271D1 (de) 1997-09-18
AU6967191A (en) 1991-07-18
DK0458937T3 (da) 1998-02-23
DE69031271T2 (de) 1998-02-26
JP2567536B2 (ja) 1996-12-25
JPH04503761A (ja) 1992-07-09
EP0458937A1 (de) 1991-12-04
ES2106772T3 (es) 1997-11-16
AU625018B2 (en) 1992-06-25
WO1991009124A1 (en) 1991-06-27
EP0458937B1 (de) 1997-08-13

Similar Documents

Publication Publication Date Title
DE69031271D1 (de) Varianten von pai-2
Potempa et al. The inactivation of human plasma alpha 1-proteinase inhibitor by proteinases from Staphylococcus aureus.
Radcliffe et al. Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII
Tsujinaka et al. Synthesis of a new cell penetrating calpain inhibitor (calpeptin)
Vissers et al. Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils.
DE69027024D1 (de) Matritzenmetalloproteinasepeptide, ihre wirkung in diagnose und therapie
Neves-Ferreira et al. Isolation and characterization of DM40 and DM43, two snake venom metalloproteinase inhibitors from Didelphis marsupialis serum
Glover et al. Synthetic peptide inhibitors of complement serine proteases—I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of C1s and D
Loskutoff Type 1 plasminogen activator inhibitor and its potential influence on thrombolytic therapy
ES8607243A1 (es) Esteres de aminoacidos y de peptidos cromogenos
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
Bradford et al. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.
Sanchez et al. Structural and functional characterization of a P-III metalloproteinase, leucurolysin-B, from Bothrops leucurus venom
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
de Agostini et al. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
Taylor et al. Induced fit activation mechanism of the exceptionally specific serine protease, complement factor D
DE69132889D1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
Mole et al. Structural evidence that complement factor B constitutes a novel class of serine protease.
Elion et al. Proteolytic derivatives of thrombin
JPH02147954A (ja) ヒトの血清または血漿におけるオステオカルシンの決定法
MX9702776A (es) Proteinas de proteasa de pulgas, moleculas de acido nucleico, y usos de las mismas.
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
Norman Effect of urea and methylamine on plasmin.
Samama et al. Crystallization and preliminary crystallographic data for bovine antithrombin III

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee